These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36037567)

  • 1. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.
    Boni V; Pistilli B; Braña I; Shapiro GI; Trigo J; Moreno V; Castellano D; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Longo F; Zaman K; Antón A; Paredes A; Huidobro G; Subbiah V
    ESMO Open; 2022 Oct; 7(5):100571. PubMed ID: 36037567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
    Cruz C; Llop-Guevara A; Garber JE; Arun BK; Pérez Fidalgo JA; Lluch A; Telli ML; Fernández C; Kahatt C; Galmarini CM; Soto-Matos A; Alfaro V; Pérez de la Haza A; Domchek SM; Antolin S; Vahdat L; Tung NM; Lopez R; Arribas J; Vivancos A; Baselga J; Serra V; Balmaña J; Isakoff SJ
    J Clin Oncol; 2018 Nov; 36(31):3134-3143. PubMed ID: 30240327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
    Kristeleit R; Leary A; Delord JP; Moreno V; Oaknin A; Castellano D; Shappiro GI; Fernández C; Kahatt C; Alfaro V; Siguero M; Rueda D; Zeaiter A; Awada A; Santaballa A; Zaman K; Sehouli J; Subbiah V
    Invest New Drugs; 2023 Oct; 41(5):677-687. PubMed ID: 37556023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
    Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; McNeish IA; Swisher EM; Ray-Coquard I; Bell-McGuinn K; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Konecny GE; Castro CM; Giordano H; Maloney L; Goble S; Lin KK; Sun J; Raponi M; Rolfe L; Kristeleit RS
    Gynecol Oncol; 2017 Nov; 147(2):267-275. PubMed ID: 28882436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
    Ghouadni A; Delaloge S; Lardelli P; Kahatt C; Byrski T; Blum JL; Gonçalves A; Campone M; Nieto A; Alfaro V; Cullell-Young M; Lubinski J
    Breast; 2017 Aug; 34():18-23. PubMed ID: 28467918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline
    Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke EM; Mina LA; Balmaña J; Fasching PA; Hurvitz SA; Wardley AM; Chappey C; Hannah AL; Robson ME;
    Clin Cancer Res; 2019 May; 25(9):2717-2724. PubMed ID: 30563931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
    Xu J; Keenan TE; Overmoyer B; Tung NM; Gelman RS; Habin K; Garber JE; Ellisen LW; Winer EP; Goss PE; Yeap BY; Chabner BA; Isakoff SJ
    Breast Cancer Res Treat; 2021 Oct; 189(3):641-651. PubMed ID: 34417675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.
    Longo-Muñoz F; Castellano D; Alexandre J; Chawla SP; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Moreno V; Sanz-García E; Awada A; Santaballa A; Subbiah V
    Eur J Cancer; 2022 Sep; 172():340-348. PubMed ID: 35830841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
    Han HS; Diéras V; Robson M; Palácová M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Garber JE; Shparyk Y; Chmielowska E; Jakobsen EH; Kaklamani V; Gradishar W; Ratajczak CK; Nickner C; Qin Q; Qian J; Shepherd SP; Isakoff SJ; Puhalla S
    Ann Oncol; 2018 Jan; 29(1):154-161. PubMed ID: 29045554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
    Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J
    Lancet; 2010 Jul; 376(9737):235-44. PubMed ID: 20609467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
    Kotani H; Masuda N; Yamashita T; Naito Y; Taira T; Inoue K; Takahashi M; Yonemori K; Toyoizumi S; Mori Y; Nagasawa T; Hori N; Iwata H
    Breast Cancer; 2022 Nov; 29(6):1088-1098. PubMed ID: 35907135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.
    Delaloge S; Wolp-Diniz R; Byrski T; Blum JL; Gonçalves A; Campone M; Lardelli P; Kahatt C; Nieto A; Cullell-Young M; Lubinski J
    Ann Oncol; 2014 Jun; 25(6):1152-8. PubMed ID: 24692579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B
    Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
    Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).
    Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
    Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
    Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
    Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
    Subbiah V; Braña I; Longhi A; Boni V; Delord JP; Awada A; Boudou-Rouquette P; Sarantopoulos J; Shapiro GI; Elias A; Ratan R; Fernandez C; Kahatt C; Cullell-Young M; Siguero M; Zeaiter A; Chawla SP
    Clin Cancer Res; 2022 Jul; 28(13):2762-2770. PubMed ID: 35486638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
    Lowery MA; Kelsen DP; Capanu M; Smith SC; Lee JW; Stadler ZK; Moore MJ; Kindler HL; Golan T; Segal A; Maynard H; Hollywood E; Moynahan M; Salo-Mullen EE; Do RKG; Chen AP; Yu KH; Tang LH; O'Reilly EM
    Eur J Cancer; 2018 Jan; 89():19-26. PubMed ID: 29223478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    Litton JK; Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Quek RGW; Markova D; Tudor IC; Hannah AL; Eiermann W; Blum JL
    N Engl J Med; 2018 Aug; 379(8):753-763. PubMed ID: 30110579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
    Tung NM; Robson ME; Ventz S; Santa-Maria CA; Nanda R; Marcom PK; Shah PD; Ballinger TJ; Yang ES; Vinayak S; Melisko M; Brufsky A; DeMeo M; Jenkins C; Domchek S; D'Andrea A; Lin NU; Hughes ME; Carey LA; Wagle N; Wulf GM; Krop IE; Wolff AC; Winer EP; Garber JE
    J Clin Oncol; 2020 Dec; 38(36):4274-4282. PubMed ID: 33119476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.